前瞻性验证研究方案:「子痫前期筛查项目」(SPREE)
SPREE 是一项在英格兰七家国民保健署产科医院开展的前瞻性多中心队列研究,纳入孕 11-13 周常规超声检查孕妇,记录母体特征、MAP、UtA-PI、血清 PAPP-A 与 PlGF 并计算子痫前期风险;假设基于贝叶斯方法的早孕期迷你联合试验与联合试验可能优于 NICE 现行仅基于母体人口学与病史的筛查方法。
要点
- SPREE 为前瞻性多中心队列研究,计划在英格兰七家国民保健署产科医院开展。
- 研究对象为孕 11-13 周常规超声检查的孕妇,按标准化方案记录母体特征、MAP、UtA-PI、PAPP-A 与 PlGF。
- 研究假设早孕期迷你联合试验与联合试验可能优于 NICE 现行筛查方法。
核心结论
- 研究假设基于贝叶斯方法的早孕期迷你联合试验与联合试验可能优于 NICE 现行仅基于母体人口学与病史的筛查方法。
研究设计与样本
- SPREE 为前瞻性多中心队列研究,方案版本 3.1(2016年11月14日),将在英格兰七家国民保健署产科医院开展。
- 纳入孕 11-13 周常规超声检查的合格孕妇,按标准化方案记录母体特征与病史及 MAP、UtA-PI、血清 PAPP-A 与 PlGF 测量值。
- 计算个体化子痫前期风险并收集妊娠结局数据,研究于 2016 年 4 月开始入组,已在 ISRCTN 注册。
关键数值与推荐
- NICE 现行指南推荐,在首次产检时,有一个主要危险因素或一个以上次要危险因素的孕妇应被建议自 12 周起每日服用低剂量阿司匹林直至分娩。
- NICE 现行筛查方法仅能识别约 35% 的子痫前期。
- 过去十年广泛研究已确立,孕 11-13 周联合母体特征与病史及 MAP、UtA-PI、血清 PlGF 与 PAPP-A 测量的贝叶斯方法对子痫前期早期预测性能最佳;仅考虑母体因素、MAP 与 PAPP-A 时可简化为迷你联合试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pre-eclampsia (PE), which affects about 2% of pregnancies, is a major cause of maternal and perinatal morbidity and mortality. Early detection of PE can improve pregnancy outcome by providing timely intervention and closer monitoring. The current guideline from the UK National Institute for Health and Care Excellence (NICE) recommends that, at the booking visit, women identified with one major risk factor or more than one moderate risk factor for PE should be advised to take low-dose aspirin daily from 12 weeks until delivery. However, performance of the current method of screening is poor and identifies only about 35% of PE. Extensive studies in the last decade have established that the best performance for early prediction of PE can be achieved by using a novel Bayes' theorem-based method that combines maternal characteristics and medical history together with measurements of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A) at 11-13 weeks' gestation. This forms the 'combined test', which could be simplified to the 'mini combined test' when only maternal factors, MAP and PAPP-A are taken into consideration. We present the protocol (version 3.1, 14 November 2016) for the 'Screening programme for pre-eclampsia' (SPREE) study, a prospective multicenter cohort study that will be carried out in seven National Health Service maternity hospitals in England. Eligible pregnant women attending their routine scan at 11-13 weeks' gestation will be invited to participate in this study. Maternal characteristics and history and measurements of MAP, UtA-PI, serum PAPP-A and PlGF will be recorded according to standardized protocols. The patient-specific risk for PE will be calculated and data on pregnancy outcomes collected. We hypothesize that the first-trimester mini combined test and combined test for PE screening, using the Bayes' theorem-based method, are likely to be superior to the current method recommended by NICE that is based on maternal demographics and history alone. Enrollment for the study commenced in April 2016. The study is registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Tan MY, Koutoulas L, Wright D, et al. Protocol for the prospective validation study: 'Screening programme for pre-eclampsia' (SPREE). Ultrasound Obstet Gynecol. 2017. PMID: 28295773. doi:10.1002/uog.17467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。